VANIHealthcare · Biotechnology

VANI Stock Forecast: Vivani Medical, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026

$1.38

0.00% on the day

The 3 Wall Street analysts covering Vivani Medical, Inc. hold a median 12-month price target of $4 — +189.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 22 Aug 2026 — in the lower half.

Market cap

$124.5M

Ticker Nerd rank

40 / 100

Median analyst target

$4.00

Analysts covering

Revenue$0.0

Operating income−$6.8M

Net income−$6.8M

Free cash flow−$6.2M

Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown

Total return, dividends reinvested

+2.2%

+7.8%

YTD

+12.2%

+11.3%

From 52W high

−26.2%

From 52W low

+47.1%

$0.94

$1.87

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

VANI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vivani Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Momentum

Issuance

Revisions

Volatility

Value

Accruals

Quality

Size (73): Smaller than most of the companies we track.

Quality (27): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VANI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VANI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts

3 Buy0 Hold0 Sell

Low $3.50Median $4.00High $4.00

The green dot is the last close — the median target sits +189.9% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
23 June 2026	Lake Street	Initiates	Buy	$4.00
31 Mar 2026	HC Wainwright & Co.	Maintains	Buy	—
2 Sept 2025	HC Wainwright & Co.	Reiterates	Buy	—
19 May 2025	HC Wainwright & Co.	Reiterates	Buy	—
16 Apr 2025	HC Wainwright & Co.	Reiterates	Buy	—
4 Apr 2025	HC Wainwright & Co.	Reiterates	Buy	—
26 Mar 2025	HC Wainwright & Co.	Reiterates	Buy	—
13 Mar 2025	HC Wainwright & Co.	Reiterates	Buy	—
7 Nov 2024	HC Wainwright & Co.	Initiates	Buy	—
5 Dec 2022	ThinkEquity	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VANI appears on the weeks it earns a place.

Performance

VANI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Vivani Medical, Inc. returned +11.3% against +19.6% for the S&P 500, dividends included.

VANI vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VANI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Vivani Medical, Inc. (VANI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −3.2×
Price / sales: —
Price / book: 6.5×
EV / EBITDA: −4.6×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −220.4%
Return on assets: −48.5%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vivani Medical, Inc. (VANI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Vivani Medical, Inc. has a market value of $124.5M and an enterprise value of $122.4M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$27.1M.
Free cash flow in the twelve months to 31 Mar 2026: −$26.5M, after $1.2M of capital spending.
Shares outstanding: 84.6M.
Trailing P/E: −3.2×; forward P/E: −3.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Vivani Medical, Inc. employs 37 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

VANI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
VANIVivani Medical, Inc.	$124.5M	40
ANIXAnixa Biosciences, Inc.	$124.4M	84
GUTSFractyl Health, Inc.	$123.7M	30
BDTXBlack Diamond Therapeutics, Inc.	$126.6M	55
INOInovio Pharmaceuticals, Inc.	$121.9M	45
GNLXGenelux Corp.	$121.6M	19
HURATuHURA Biosciences, Inc.	$121.4M	18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vivani Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VANI news & analysis

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 13 Aug 2026positive

Vivani Medical reported Q2 2026 financial results, noting all participants were successfully dosed in the Phase 1 trial of NPM-139, a semaglutide implant for weight management, with top-line data expected in November 2026. The company also entered a non-exclusive agreement with Novo Nordisk and anticipates the Cortigent-ClearOne merger completion in Q3 2026.

Why it matters — VANI watchers would care because progress in the NPM-139 clinical trial and the Novo Nordisk agreement represent key milestones for the company's lead pipeline candidate and technology validation.

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

GlobeNewsWire · 6 Aug 2026positive

Vivani Medical announced successful dosing of all participants in SLIM-1, its Phase 1 trial evaluating NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management. Dosing of the first participant began ahead of schedule and was rapidly followed by initial dosing across all trial participants.

Why it matters — A VANI watcher would care because completing dosing of all participants marks tangible clinical progress for NPM-139, the company's lead investigational treatment for chronic weight management.

FAQ

Frequently asked questions about VANI stock

What is the VANI stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Vivani Medical, Inc. have a median 12-month price target of $4, with estimates ranging from $3.5 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VANI stock a buy right now?

Of the 3 analysts covering Vivani Medical, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vivani Medical, Inc. 40 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VANI?

As at 22 Aug 2026, Vivani Medical, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (73 of 100).

Will VANI stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +189.9% from the last close, and Ticker Nerd's factor model ranks Vivani Medical, Inc. 40 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VANI stock forecast for 2030?

No analyst covering Vivani Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VANI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $4 over the next 12 months.

How has VANI stock performed over the past year?

Vivani Medical, Inc. returned +11.3% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vivani Medical, Inc. do?

Vivani Medical Inc. is a specialized biotechnology and medical device company focused on developing innovative solutions in the healthcare sector.

What is the latest news on VANI?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update". Vivani Medical reported Q2 2026 financial results, noting all participants were successfully dosed in the Phase 1 trial of NPM-139, a semaglutide implant for weight management, with top-line data expected in November 2026. The company also entered a non-exclusive agreement with Novo Nordisk and anticipates the Cortigent-ClearOne merger completion in Q3 2026.

Company

About Vivani Medical, Inc.

Vivani Medical Inc. is a specialized biotechnology and medical device company focused on developing innovative solutions in the healthcare sector. Their primary focus is on addressing chronic diseases and improving patient outcomes through the integration of advanced technologies in bioelectronics. Vivani Medical is particularly notable for its work in creating cutting-edge, implantable medical devices designed to enhance the quality of life for individuals living with sensory deficits and chronic pain. This company operates at the intersection of bioengineering and healthcare, pioneering efforts in providing long-term therapeutic solutions. With a commitment to improving health outcomes, Vivani Medical's developments have potential implications across various medical fields, including neuroscience and chronic disease management, thus playing a significant role in the evolving landscape of medical technology. Their innovative approach underscores the growing importance of bioelectronic medicine as an emerging field that holds promise for addressing some of the most challenging health issues.

CEO Dr. Adam Mendelsohn Ph.D. · 37 employees · United States · https://www.vivani.com